Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

2.

Medicaid expansion tied to smaller declines in early-stage cancer detection

3.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

4.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

5.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot